Rubino, Christopher M.
Onufrak, Nikolas J.
van Ingen, Jakko
Griffith, David E.
Bhavnani, Sujata M.
Yuen, Dayton W.
Mange, Kevin C.
Winthrop, Kevin L.
Funding for this research was provided by:
Insmed Incorporated
Article History
Accepted: 27 December 2020
First Online: 17 February 2021
Change Date: 19 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13318-021-00687-z
Declarations
:
: This work and the Open Access fee for the published article were supported by Insmed Incorporated, Bridgewater, NJ, USA.
: ICPD Inc received funding from Insmed Incorporated to conduct the analysis and provide general consulting to Insmed. DEG has received consulting fees and research grants from Insmed. JvI is a member of the Insmed Advisory Board. DWY and KCM are employed by Insmed. KLW has received consulting fees and research grants from Insmed.
: The clinical studies TR02-112 (NCT01315236) and CONVERT (NCT02344004) were conducted in accordance with the principles of Good Clinical Practice and Declaration of Helsinki. The study protocols were approved by an independent ethics committee or institutional review board for each site.
: All patients provided written informed consent.
: Not applicable.
: Not applicable.
: Not applicable.
: The authors made the following contributions: authors from the Institute for Clinical Pharmacodynamics, Inc (ICPD, Schenectady, NY, USA), and Insmed Incorporated (Bridgewater, NJ, USA) designed the study; KLW and DEG were trial investigators. CMR, NJO, and SMB conducted the analyses. CMR, NJO, JvI, KLW, DWY, and KCM interpreted the data. CMR, NJO, JvI, KLW, and DWY drafted the content. All authors provided critical review and approval of the manuscript.